US FDA Revisits PD-L1 Biomarker In Gastric, Esophageal Cancers

The Oncologic Drugs Advisory Committee will discuss restrictions for patients expressing  PD-L1 in first-line labeling for Merck’s Keytruda, Bristol Myers Squibb’s Opdivo, and a pending NDA for BeiGene’s Tevimbra.